Fulcrum granted the new employee 63,000 options to purchase shares of the company's common stock at an exercise price of $3.81 per share, the closing price per share of Fulcrum's common stock as ...

In this article, we will discuss the 12 Best Healthcare Stocks to Buy According to Analysts. McKinsey reported that, since ...

Bushra Sumra’s career highlights the profound impact that expertise in clinical research and regulatory compliance can have ...

Custom duty waiver for expensive cancer drugs doesn't address high prices due to patent monopolies, offering minimal relief ...

GeneDX Holdings reports Q4 earnings on February 18th. Find out why WGS stock is a strong play in the booming genetics testing ...

In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...

Through policy framework shifts, appeals to the court for rare disease funds, and starting a centre in Bengaluru, Prasanna ...

DEBRA Research and LEO Pharma enter strategic partnership to advance treatments for rare skin diseases: Munich, Germany Thursday, February 6, 2025, 10:00 Hrs [IST] DEBRA Research ...

Inspired by the rare disease community’s passionate drive to advance policies that provide equitable access to care, UCB ...

Set to enter hospice care, a patient with idiopathic multicentric Castleman's disease is now in remission after treatment with a medication identified by an AI-guided analysis.

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).